for p values). There is also a decrease in or plasmid encoding PLP 139-151 produced no detectable the incidence of disease and mean peak disease severproduct ( Figure 1A, lane 3) . The predicted molecular ity with the covaccine. The onset of disease was not weight for PLP 139-151 is approximately 1.5 kDa and, theresignificantly delayed compared to the control groups fore, would be extremely difficult to visualize by electro-(data not shown). phoresis. also injected as a control. As shown in Figure 3G, Table  2 ). The wild-type BALB/c mice covaccinated with MBP and IL-4 DNA had a greater amount of deviation to Th2 cytokine production (Th2/Th1 ratio of 1.9) than in any of the other groups, including the STAT6 knockout mice. Therefore, STAT6 is required in order for the covaccine to produce a Th2 shift in cytokine production by myelinspecific T cells. Figure 4) . There is also a significant difference in also express IL-4, which is secreted locally during the the mean peak disease severity after DNA administration APC and T cell interaction. This secreted IL-4 then (see Table 3 over traditional treatments of autoimmune disease is When the cytokine profile of T cells from covaccinated the ability to easily modify the treatment vehicle. We and protected mice was examined, a shift to a Th2-type have shown here that, with the addition of a genetically of cytokine secretion pattern was seen. Furthermore, delivered IL-4 cytokine to a myelin-encoding DNA vacthese Th2 cells could transfer protection against disease cine, we can protect against and reverse established induction in naive mice. EAE and, further, drive the protective response to a more Additionally, we demonstrate that DNA vaccination Th2 type. We have previously reported that vaccination can be used to reverse ongoing EAE. When mice with with DNA encoding the V␤8.2 variable region of a T cell active EAE were covaccinated with separate plasmids receptor (TCR) that is important in the pathogenesis of encoding MOG and IL-4, the mice had a reduction in EAE is effective in protecting against EAE and causes several disease parameters. Mice vaccinated with MOGthe myelin-reactive T cells to become more Th2-like or IL-4-encoding DNA alone did not have significant (Waisman et al., 1996) . However, such a strategy would EAE reduction. These results thus demonstrate that DNA be prohibitive in widespread clinical trials or in other vaccination can be used to treat established EAE in autoimmune diseases because it requires the knowladdition to the prevention of EAE onset and that IL-4-edge of the exact TCR repertoire relevant for a particular encoding DNA is required as a covaccine for this disease and for a particular individual. The obvious adtreatment.
IL-

Covaccination with DNA Encoding
vantage of an IL-4 DNA covaccine is that it can be easily We thus propose that the combination of the local included along with the antigen-specific DNA vaccine delivery of IL-4 and vaccination with myelin-encoding for a particular autoimmune disease.
DNA causes the antigen-specific autoreactive T cells to
We have also previously reported that, after DNA vacshift their phenotype to a more protective Th2-type of cination with a myelin epitope alone, T cells are anergic response. These antigen-specific, protective T cells are Cytokine Profile Determination run on an 18% SDS polyacrylamide gel. After drying, the gel was T cell lines were established from LNCs derived from DNA-vaccithen exposed to autoradiography film. nated mice as previously described (Waisman et al., 1996). These T cells were then tested for the production of various cytokines. T cells (50 ϫ 10 3 /ml) were incubated with 2.5 ϫ 10 6 irradiated syngenic STAT6 Westerns After dissection of draining lymph nodes from DNA-vaccinated mice, APCs/ml in enriched RPMI and 10% FCS. After 6 days of culture, the supernatants were collected and tested by sandwich ELISA the tissues were mechanically homogenized in 1 ml of the following buffer: 0.1 M NaCl, 0.01 M Tris-HCL (pH7.4), 0.001 M EDTA, 1 g/ using standard ELISA kits (PharMingen).
